Genetic Signatures Limited (ASX:GSS)

Market Cap	97.67M
Revenue (ttm)	18.66M
Net Income (ttm)	-22.59M
Shares Out	227.14M
EPS (ttm)	-0.11
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	15,237
Average Volume	56,346
Open	0.4000
Previous Close	0.4300
Day's Range	0.4000 - 0.4050
52-Week Range	0.3600 - 0.8500
Beta	0.73
RSI	41.89
Earnings Date	May 26, 2025

About Genetic Signatures

Genetic Signatures Limited operates as a molecular diagnostic company in Australia, the Asia Pacific, Europe, the Middle East, Asia, and the Americas. The company offers enteric bacteria, Enteroaggregative E.coli aggR and aaiC, enteric viral, enteric protozoan, enteric protozoan extended, enteric microsporidia, respiratory pathogen, SARS-CoV-2, SARS-CoV-2 respiratory plus, coronavirus, atypical respiratory, pertussis and PCP, parainfluenza 4, STI genital pathogen, extended spectrum beta-lactamase and carbapenemase producing organisms, viral men...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2001
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: GSS

Financial Performance

In 2024, Genetic Signatures's revenue was 13.77 million, a decrease of -36.00% compared to the previous year's 21.51 million. Losses were -17.86 million, 27.1% more than in 2023.